Federal Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Diabetes Guidelines Move GLP-1s Up Front
Tuesday, October 6, 2026 · 11 min
Federal employee health plans will require documented intensive behavioral therapy before and during anti-obesity drug treatment in 2027, while the new ADA-EASD consensus backs GLP-1 or SGLT2 drugs early in type 2 diabetes. Plus a phase 3 oral GLP-1 pill, a new SELECT heart analysis, and what's known about GLP-1s in children.
Listen
Show notes
Federal employee health plans will require documented intensive behavioral therapy before and during anti-obesity drug treatment in 2027, while the new ADA-EASD consensus backs GLP-1 or SGLT2 drugs early in type 2 diabetes. Plus a phase 3 oral GLP-1 pill, a new SELECT heart analysis, and what's known about GLP-1s in children.
In this episode
- 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com — Ian Smith
# 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com Author: Ian Smith Published: 2026-10-05T16:40:00Z Source: fedsmith.com Language: en ## Story 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com # 2027 FEHB Changes: Weight Loss Drug Rules, a New FSA Card, and Plans Leaving From weight loss drug rules to a new…
- The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest — Peptide News Digest
The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest Evidence Brief October 4, 2026 · 7 min read # The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin The American Diabetes Association and the European Association for the Study of Diabetes…
- Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine — Nature Medicine
# Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine Author: Guo, Lixin, Yu, Dongni, Xu, Yimei, Tang, Guo, Peng, Liang Published: 2026-10-05T10:54:20Z Source: nature.com Language: en ## Story Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a…
- Semaglutide heart benefits not fully explained by weight loss - The Pharmacist — Victoria Vaughan
Semaglutide heart benefits not fully explained by weight loss - The Pharmacist # Semaglutide heart benefits not fully explained by weight loss By Jerome Smail 5th October 2026 aprott / iStock / Getty Images Plus The cardiovascular benefits of the GLP-1 receptor agonist semaglutide cannot be fully explained by weight loss or improvements in other known risk factors, according to a new…
- Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact — Madison Czopek
Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact # Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know Doses of Wegovy, a drug used for weight loss, are stored in a refrigerator at Donna Cooper's home in Front Royal, Va., on March 1, 2024. (AP) By Madison Czopek October 5, 2026 #### If…